If it is able to implement its strategic goals, Myriad projected, it could have $1.5 billion in annual revenues by fiscal year 2020.
Fiscal fourth quarter revenues were $189.9 million, while fiscal year revenues totaled $723.1 million.
So far, results from the MSK-IMPACT test have been reported for more than 4,500 patients.
Data presented at the meeting helped better define the potential benefits and risks of broad panel-based tests for hereditary cancer genes.
The agency has described detailed situations under which it will cover BRCA testing and multi-gene panels for assessing risk for hereditary cancer syndromes.
The company attributed its third quarter revenue decline to bad weather.
The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.
The deal between the firms grants Quest the rights to use Genomic Vision's technology to develop tests for breast and ovarian cancer, among other diseases.
The research also uncovered other mutations that might be associated with these cancers in patients who do not have a CDH1 mutation.
In addition to the drop in revenues, Myriad lowered its FY 2015 revenue guidance.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.